 | |
| Clinical data | |
|---|---|
| Other names | PS-178990 |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.233.303 |
| Chemical and physical data | |
| Formula | C14H12ClN3O3 |
| Molar mass | 305.72 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
BMS-564,929 is an investigationalselective androgen receptor modulator (SARM) which is being developed byBristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). These symptoms may includedepression, loss ofmuscle mass andstrength, reduction inlibido andosteoporosis. Treatment with exogenoustestosterone is effective in counteracting these symptoms but is associated with a range of side effects, the most serious of which is enlargement of theprostate gland, which can lead tobenign prostatic hyperplasia and evenprostate cancer. This means there is a clinical need for selective androgen receptor modulators, which produceanabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in the prostate.[1]
BMS-564,929 is one such compound currently in early human clinical trials, which is an orally active, potent, and selective agonist for androgen receptors (Ki 2.1nM, 20xfunctional selectivity for muscle tissue over prostate) and in studies on castrated rats it was shown to counteract the decrease in muscle mass over time, and at higher doses even increased muscle mass, without significantly affecting prostate tissue.[2] It does however vastly reduceluteinizing hormone levels, it being an astonishing 33× more suppressive compound than testosterone, which may be a problem in human clinical use.[3]
Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar toanabolic steroids but with significantly fewer side effects. For this reason, SARMs have already been banned by theWorld Anti-Doping Agency since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed.[4][5]